{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179828","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.025414+00:00","generated_at":"2026-05-17T13:58:26.657531+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jade Biosciences Q2 net loss $32.1M; cash $220.9M; JADE101 Phase 1 starts Q3","bullets":["Net loss of $32.1M for Q2 2025; R&D expense $22.5M, G&A $5.2M; non-cash stock comp $4.0M.","Cash and cash equivalents of $220.9M as of June 30, 2025; expected runway through 2027.","JADE101 preclinical data presented; Phase 1 healthy-volunteer study to begin Q3 2025 with interim data H1 2026.","Appointed Brad Dahms as CFO; previously CFO at IDRx, Theseus, Selecta.","JADE201 development candidate from JADE-002 program on track for clinic in H1 2026; details expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179828","json":"https://secwatch.observer/filing/0001193125-25-179828.json","markdown":"https://secwatch.observer/filing/0001193125-25-179828.md","text":"https://secwatch.observer/filing/0001193125-25-179828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312525179828/0001193125-25-179828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312525179828/d82765d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:26.657531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}